Novartis AG (NVS)
158.00
-0.86
(-0.54%)
USD |
NYSE |
Aug 24, 16:00
158.00
0.00 (0.00%)
After-Hours: 20:00
Novartis EPS Diluted (Quarterly) : 1.706 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.706 |
| March 31, 2026 | 1.654 |
| December 31, 2025 | 1.249 |
| September 30, 2025 | 2.020 |
| June 30, 2025 | 2.095 |
| March 31, 2025 | 1.822 |
| December 31, 2024 | 1.396 |
| September 30, 2024 | 1.573 |
| June 30, 2024 | 1.586 |
| March 31, 2024 | 1.307 |
| December 31, 2023 | 4.106 |
| September 30, 2023 | 0.8487 |
| June 30, 2023 | 1.105 |
| March 31, 2023 | 1.084 |
| December 31, 2022 | 0.686 |
| September 30, 2022 | 0.7186 |
| June 30, 2022 | 0.7662 |
| March 31, 2022 | 0.9933 |
| December 31, 2021 | 7.238 |
| September 30, 2021 | 1.224 |
| June 30, 2021 | 1.282 |
| March 31, 2021 | 0.909 |
| December 31, 2020 | 0.9176 |
| September 30, 2020 | 0.8406 |
| June 30, 2020 | 0.8103 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.9494 |
| December 31, 2019 | 0.4908 |
| September 30, 2019 | 0.889 |
| June 30, 2019 | 2.914 |
| March 31, 2019 | 0.755 |
| December 31, 2018 | 0.511 |
| September 30, 2018 | 0.6985 |
| June 30, 2018 | 3.301 |
| March 31, 2018 | 0.8667 |
| December 31, 2017 | 0.84 |
| September 30, 2017 | 0.88 |
| June 30, 2017 | 0.83 |
| March 31, 2017 | 0.70 |
| December 31, 2016 | 0.40 |
| September 30, 2016 | 0.81 |
| June 30, 2016 | 0.75 |
| March 31, 2016 | 0.84 |
| December 31, 2015 | 0.44 |
| September 30, 2015 | 0.77 |
| June 30, 2015 | 0.75 |
| March 31, 2015 | 5.32 |
| December 31, 2014 | 0.61 |
| September 30, 2014 | 1.31 |
| June 30, 2014 | 1.050 |
| March 31, 2014 | 1.221 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Roche Holding AG | -- |
| AstraZeneca PLC | 0.9849 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
| Merck & Co., Inc. | -0.5405 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 3.259B |
| Revenue (Quarterly) | 14.42B |
| Total Expenses (Quarterly) | 11.15B |
| Enterprise Value | 332.53B |
| Gross Profit Margin (Quarterly) | 74.47% |
| Profit Margin (Quarterly) | 22.61% |
| Earnings Yield | 4.20% |
| Operating Earnings Yield | 5.33% |
| Normalized Earnings Yield | 4.503 |